KMI169 is a potent and selective bi-substrate inhibitor targeting the SAM and substrate binding pockets of KMT9. KMI169 can be used for the research of prostate cancer.
References:
[1]. Wang S, et al. Structure-guided design of a selective inhibitor of the metltransferase KMT9 with cellular activity. Nat Commun. 2024 Jan 2;15(1):43.
















